九典制药
(300705)
| 流通市值：64.99亿 | | | 总市值：87.93亿 |
| 流通股本：3.67亿 | | | 总股本：4.96亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,145,889,147.01 | 1,366,190,189.06 | 590,896,382.47 | 2,692,511,461.24 |
| 营业收入 | 2,145,889,147.01 | 1,366,190,189.06 | 590,896,382.47 | 2,692,511,461.24 |
| 二、营业总成本 | 1,683,616,597.25 | 1,091,540,764.04 | 472,495,995.84 | 2,314,990,942.39 |
| 营业成本 | 563,073,361.04 | 366,951,223.6 | 161,665,602.27 | 615,217,177.11 |
| 税金及附加 | 25,161,702.71 | 15,720,249.13 | 6,853,696.4 | 34,212,152.61 |
| 销售费用 | 855,062,640.57 | 546,256,965.63 | 239,316,247.27 | 1,307,431,808.44 |
| 管理费用 | 61,321,830.35 | 40,892,659.13 | 19,699,811.98 | 97,987,986.03 |
| 研发费用 | 167,429,052.23 | 114,005,004.98 | 40,928,107.97 | 254,121,849.65 |
| 财务费用 | 11,568,010.35 | 7,714,661.57 | 4,032,529.95 | 6,019,968.55 |
| 其中:利息费用 | 15,516,276.94 | 10,407,459.56 | 5,221,015.81 | 11,061,725.58 |
| 其中:利息收入 | 4,281,217.93 | 2,946,832.17 | 1,414,246.85 | 5,535,934.21 |
| 加:公允价值变动收益 | 0 | 0 | 0 | 0 |
| 加:投资收益 | 2,541,117.47 | 1,508,211.42 | 580,456.19 | 2,132,585.94 |
| 净敞口套期收益 | 0 | 0 | 0 | 0 |
| 资产处置收益 | 0 | 0 | 0 | 30,283.93 |
| 资产减值损失(新) | -3,593,078.26 | -2,792,912.7 | -2,542,389.59 | -6,570,476.86 |
| 信用减值损失(新) | 4,851,799.29 | 7,128,294.73 | 5,980,539.21 | -7,808,360.95 |
| 其他收益 | 41,834,753.24 | 37,796,525.54 | 24,872,049.39 | 29,065,685.43 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 507,907,141.5 | 318,289,544.01 | 147,291,041.83 | 394,370,236.34 |
| 加:营业外收入 | 671,453.42 | 433,754.09 | 285,274.53 | 10,405,332.94 |
| 减:营业外支出 | 2,819,130.93 | 2,065,365.34 | 1,946,013.49 | 2,614,585.61 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 505,759,463.99 | 316,657,932.76 | 145,630,302.87 | 402,160,983.67 |
| 减:所得税费用 | 56,024,682.12 | 32,527,444.07 | 19,960,829.75 | 33,900,192.99 |
| 六、净利润 | 449,734,781.87 | 284,130,488.69 | 125,669,473.12 | 368,260,790.68 |
| 持续经营净利润 | 449,734,781.87 | 284,130,488.69 | 125,669,473.12 | 368,260,790.68 |
| 终止经营净利润 | 0 | 0 | 0 | 0 |
| 归属于母公司股东的净利润 | 449,734,781.87 | 284,130,488.69 | 125,669,473.12 | 368,260,790.68 |
| 少数股东损益 | 0 | 0 | 0 | - |
| (一)基本每股收益 | 0.93 | 0.59 | 0.36 | 1.07 |
| (二)稀释每股收益 | 0.92 | 0.59 | 0.36 | 1.07 |
| 八、其他综合收益 | 2,788,850 | 2,788,850 | 0 | 0 |
| 归属于母公司股东的其他综合收益 | 2,788,850 | 2,788,850 | 0 | 0 |
| 九、综合收益总额 | 452,523,631.87 | 286,919,338.69 | 125,669,473.12 | 368,260,790.68 |
| 归属于母公司股东的综合收益总额 | 452,523,631.87 | 286,919,338.69 | 125,669,473.12 | 368,260,790.68 |
| 归属于少数股东的综合收益总额 | 0 | 0 | 0 | 0 |
| 公告日期 | 2024-10-29 | 2024-08-24 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |